πŸ‡ΊπŸ‡Έ FDA
Patent

US 10562934

Modulation of complement activity

granted A61KA61K38/00A61K47/64

Quick answer

US patent 10562934 (Modulation of complement activity) held by RA PHARMACEUTICALS, INC. expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
RA PHARMACEUTICALS, INC.
Grant date
Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K38/00, A61K47/64, A61K47/645, A61P